Drug Trial Radar · NCT07653100
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Jun 22, 2026
Primary completion
Jan 25, 2027
Study completion Jan 25, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
Conditions
- Respiratory Syncytial Virus (RSV)
Interventions
RSVpreFBiological
RSVpreF Vaccine
PlaceboBiological
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants reporting local reactions within 7 days following investigational product administrationTime frame: Within 7 days
- Percentage of participants reporting systemic events within 7 days following investigational product administrationTime frame: Within 7 days
- Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administrationTime frame: 1 month after vaccination
- Percentage of participants reporting serious adverse events (SAEs) throughout the studyTime frame: 3 months after vaccination
- Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titers (GMT)Time frame: Before vaccination, 1 month after vaccination
- NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)Time frame: Before vaccination, 1 month after vaccination
- NTs for RSV A and RSV B expressed as seroresponse rateTime frame: 1 month after vaccination
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
King George Hospital
Visakhapatnam, Andhra Pradesh, India · Recruiting
BGS Global Institute of Medical Sciences (BGSGIMS)
Bangalore, Karnataka, India · Recruiting
Radhakrishna Multispeciality Hospital and IVF Center
Bangalore, Karnataka, India · Recruiting
Belagavi Institute of Medical Sciences - Belagavi
Belagavi, Karnataka, India · Recruiting
Suyog Hospital
Nashik, Maharashtra, India · Recruiting
Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre
Pune, Maharashtra, India · Recruiting
Aakash Healthcare Private Limited
Dwarka, National Capital Territory of Delhi, India · Recruiting
All India Institute Of Medical Sciences
New Delhi, National Capital Territory of Delhi, India · Recruiting
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, India · Recruiting
Maharaja Agrasen Superspeciality Hospital
Jaipur, Rajasthan, India · Recruiting
SRM Medical College Hospital and Research Centre - Kattankulathur
Chengalpattu, Tamil Nadu, India · Recruiting
Chettinad Hospital and Research Institute
Kelambākkam, Tamil Nadu, India · Recruiting
Institute of Post Graduate Medical Education & Research, SSKM Hospital
Kolkata, West Bengal, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.